Bumetanide Nasal Spray: First Approval.

IF 3.1 3区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical Drug Investigation Pub Date : 2026-02-01 Epub Date: 2025-11-12 DOI:10.1007/s40261-025-01503-1

Hannah A Blair

引用次数: 0

Abstract

Bumetanide nasal spray (ENBUMYST^™) is a loop diuretic developed by Corstasis Therapeutics for the treatment of oedema. It is designed as a short-term therapeutic option, with absorption via the nasal mucosa potentially offering more consistent or predictable bioavailability than oral administration, particularly in patients with gastrointestinal impairment. Bumetanide nasal spray received its first approval on 12 September 2025 in the USA for the treatment of oedema associated with congestive heart failure (CHF), and hepatic and renal disease, including nephrotic syndrome in adults. This article summarizes the milestones in the development of bumetanide nasal spray leading to this first approval for the treatment of oedema.

查看原文本刊更多论文

布美他尼鼻喷雾剂：首次批准。

布美他尼鼻喷雾剂（ENBUMYST™）是Corstasis Therapeutics公司开发的用于治疗水肿的环状利尿剂。它被设计为一种短期治疗选择，与口服给药相比，通过鼻黏膜吸收可能提供更一致或可预测的生物利用度，特别是对于胃肠道损伤患者。布美他尼鼻喷雾剂于2025年9月12日在美国首次获得批准，用于治疗成人充血性心力衰竭（CHF）和肝脏和肾脏疾病（包括肾病综合征）相关的水肿。这篇文章总结了布美他尼鼻喷雾剂发展的里程碑，导致首次批准用于治疗水肿。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Drug Investigation 医学-药学

CiteScore

5.90

自引率

3.10%

发文量

108

审稿时长

6-12 weeks

期刊介绍： Clinical Drug Investigation provides rapid publication of original research covering all phases of clinical drug development and therapeutic use of drugs. The Journal includes: -Clinical trials, outcomes research, clinical pharmacoeconomic studies and pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs. -Clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice. -Pharmacodynamic and pharmacokinetic studies in healthy volunteers in which significant implications for clinical prescribing are discussed. -Studies focusing on the application of drug delivery technology in healthcare. -Short communications and case study reports that meet the above criteria will also be considered. Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Clinical Drug Investigation may be accompanied by plain language summaries to assist readers who have some knowledge, but non in-depth expertise in, the area to understand important medical advances.